Search

Displaying results 491 - 500 of 7059 in total
  1. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

    Categories: MATE 2 Substrates with a Narrow Therapeutic Index, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index
  2. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

  3. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … by an FDA-approved test [L2939].

  4. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. … [L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]

    Mixtures: Hyzaar DS, SARAVANTA-DProducts: LOSARTAN DR. REDDY'S, LOSARTAN 25 1A PHARMA
  5. Drug

    Ornidazole

    go.drugbank.com/drugs/DB13026
    Investigational

    Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

    Products: TIBERAL ROCHE DE 500 MG
  6. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    It is currently marketed under the brand name Prevymis.[L1021] … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

    Categories: DNA Terminase Complex Inhibitors, Cytomegalovirus DNA Terminase Complex Inhibitor
  7. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).

  8. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    It was approved in Europe in February 2015, and in the United States on March 21, 2017.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  9. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    [A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … [A174124] Valsartan is generally well-tolerated with a side-effect profile superior to that of other antihypertensive drugs.[A174130,A174133]

    Mixtures: DI-TANVLUR, VARTALAN D PLUS TABLETA RECUBIERTAProducts: VALSARTAN DR. REDDY'S, VALSARTAN 1A PHARMA 40MG
  10. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    [A177541] There is a dose-related effect of psychostimulants on receptor stimulation, where higher doses are shown to increase norepinephrine (NE) and dopamine (DA) efflux throughout the brain which can … In contrast, low doses are found to selectively activate NE and DA neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology,

    Products: RITALINA® LA 20 MG CAPSULAS DE LIBERACION PROLONGADA, Ritalin LA